Experienced in Plasmacytoma

Dr. David A. Clump

Radiation Oncology
West Virginia University Medical Corporation
1 Medical Ctr Dr, 
Morgantown, WV 
Clinical Trials:Currently Recruiting for 5 Trials
Accepting New Patients
Offers Telehealth
Experienced in Plasmacytoma
West Virginia University Medical Corporation
1 Medical Ctr Dr, 
Morgantown, WV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Clump is a Radiation Oncologist in Morgantown, West Virginia. Dr. Clump is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, and Oral Squamous Cell Carcinoma. Dr. Clump is currently accepting new patients.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in WV
Hospital Affiliations
St Joseph's Hospital Of Buckhannon, Inc
United Hospital Center, Inc
West Virginia University Hospitals, Inc
Mon Health Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

WEST VIRGINIA UNIVERSITY MEDICAL CORPORATION
1 Medical Ctr Dr, Morgantown, WV 26506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Intervention Type: Radiation, Drug
Study Drug: AZD1390
Study Phase: Phase 1
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Recruiting
Publish Date: June 19, 2025
Intervention Type: Procedure, Other, Drug, Radiation
Study Phase: Phase 2
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Device
Study Phase: Not Applicable
Phase II Study Determining the Efficacy of Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
Phase II Study Determining the Efficacy of Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
Enrollment Status: Completed
Publish Date: June 26, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES
PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases
A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Docetaxel
Study Phase: Phase 2
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin, Cetuximab
Study Phase: Phase 1
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer
A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Radiation
Study Phase: Not Applicable
Measuring the Effect of Radiation Therapy on Patient Activity Levels
Measuring the Effect of Radiation Therapy on Patient Activity Levels
Enrollment Status: Terminated
Publish Date: August 09, 2018
View 15 Less Clinical Trials

78 Total Publications

Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review.
Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review.
Journal: Cancers
Published: August 25, 2025
Similar Doctors
Experienced in Plasmacytoma
Dr. Muhammad M. Fareed
Radiation Oncology
Experienced in Plasmacytoma
Dr. Muhammad M. Fareed
Radiation Oncology

West Virginia University Medical Corporation

1 Medical Ctr Dr, 
Morgantown, WV 
 (0.1 miles away)
304-293-4500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Muhammad Fareed is a Radiation Oncologist in Morgantown, West Virginia. Dr. Fareed is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Plasmacytoma, Familial Prostate Cancer, and Vertebroplasty. Dr. Fareed is currently accepting new patients.

Experienced in Plasmacytoma
Dr. Joel S. Greenberger
Radiation Oncology
Experienced in Plasmacytoma
Dr. Joel S. Greenberger
Radiation Oncology
200 Lothrop St, Suite B-354, 
Pittsburgh, PA 
 (54.5 miles away)
412-647-5715
Languages Spoken:
English
See accepted insurances

Joel Greenberger is a Radiation Oncologist in Pittsburgh, Pennsylvania. Dr. Greenberger is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Congenital Aplastic Anemia, Pulmonary Fibrosis, Radiation Sickness, and Plasmacytoma.

Experienced in Plasmacytoma
Dr. Daryl Y. Makishi
Radiation Oncology | Radiology
Experienced in Plasmacytoma
Dr. Daryl Y. Makishi
Radiation Oncology | Radiology

Allegheny Clinic

2600 Haymaker Rd, 
Monroeville, PA 
 (54.6 miles away)
412-856-7740
Languages Spoken:
English
See accepted insurances

Daryl Makishi is a Radiation Oncologist and a Radiologist in Monroeville, Pennsylvania. Dr. Makishi is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Breast Cancer, Prostate Cancer, Familial Prostate Cancer, and Primitive Neuroectodermal Tumor (PNET).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Clump's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile